Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3689-3698

  Jeng, Jen Eing ^a   Tsai, Meng Feng ^b   Tsai, Hey Ru ^c   Chuang, Lea Yea ^d   Lin, Zu Yau ^a   Hsieh, Min Yuh ^a   Chen, Shinn Chern ^a   Chuang, Wan Lung ^a   Wang, Liang Yen ^a   Yu, Min Lung ^a   Dai, Chia Yen ^a   Tsai, Jung Fa ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAINAN SIN LAU HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Receiver operating characteristic curve; Transforming growth factor ; Tumor marker; Urine; Fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CREATININE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SERUM; URINE LEVEL;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 84899085480     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1488-2     Document Type: Article

References (34)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-55.
2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence - SEER 9 Regs research data, Nov 2009 Sub (1973-2007). Bethesda: National Cancer Institute; 2010.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
4. Terentiev AA, Moldogazieva NT. alpha-Fetoprotein: a renaissance. Tumor Biol. 2013;34:2075-91.
5. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation global guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointest Liver Dis. 2010;19:311-7.
6. Jeng JE, Chuang LY, Chuang WL, Tsai JF. Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma. Chin Clin Oncol. 2012;1:4.
7. Tsai JF, Jeng JE, Chuang LY, You HL, Wang LY, Hsieh MY, et al. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scand J Gastroenterol. 2005;40:68-75.
8. Wang L, Yao M, Dong Z, Yun Z, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumor Biol. 2013. doi: 10.1007/s13277-013-1141-0.
9. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570-5.
10. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Clinical evaluation of urinary transforming growth factor-β1 and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Br J Cancer. 1997;75:1460-6.
11. Tsai JF, Jeng JE, Chuang LY, You HL, Ho MS, Lai CS, et al. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Tumor Biol. 2003;24:291-8.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
13. Shen Q, Fan J, Yang XR, Tan YX, Zhao WF, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817-26.
14. Jeng JE, Chuang LY, Chuang WL, Tsai JF. Insulin-like growth factor II in hepatocellular carcinoma. Biomark Med. 2007;1:261-71.
15. Fausto N, Campbell JS. Liver regeneration. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Fausto N, Shaftritz DA, Wolfoff AW, editors. The liver: biology and pathobiology. 5th ed. Hoboken: Wiley-Blackwell; 2009. p. 549-66.
16. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19:318-25.
17. Pannain VL, Morais JR, Damasceno-Ribeiro O, Avancini-Alves V. Transforming growth factor α immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue. Ann Hepatol. 2012;11:495-9.
18. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis. Int J Oncol. 2013;42:1133-8.
19. Zhang J, Wang WL, Li Q, Qiao Q. Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol. 2004;10:830-3.
20. Tomiya T, Fijiwara K. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis. Cancer. 1996;77:1056-60.
21. Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE. The expression of transforming growth factor-α in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases. Am J Surg Pathol. 2007;31:681-9.
22. Yeh YC, Tsai JF, Chuang LY, Yeh HW, Tsai JH, Florine DL, et al. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 1987;47:896-901.
23. Chuang LY, Tsai JH, Yeh YC, Chang CC, Yeh HW, Guh JY, et al. Epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma. Hepatology. 1991;13:1112-6.
24. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. AJCC cancer staging manual. 6th ed. Chicago: Springer; 2002. p. 435.
25. Tsai JF, Chang WY, Jeng JE, Wang LY, Hsieh MY, Chen SC, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol. 1993;41:296-300.
26. Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R. Transection of the esophagus for bleeding esophageal varices. Br J Surg. 1973;60:646-9.
27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison's principles of internal medicine, 18th ed: Chapter 3. Decision-making in clinical medicine. New York: McGraw-Hill; 2012. http://www.accessmedicine. com.
28. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285-93.
29. Baker SG. Improving the biomarker pipeline to develop and evaluate cancer screening test. J Natl Cancer Inst. 2009;101:1116-9.
30. Balcan E, Demirkiran F, Aydin Y, Saniogluc C, Bese T, Arvas M, et al. Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer. Gynecol Cancer. 2012;22:1138-42.
31. Yoshida K, Kyo E, Tsuda T, Tsujino T, Ito M, Niimoto M, et al. TGF-alpha, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int J Cancer. 1990;45:131-5.
32. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinoma. Jpn J Clin Oncol. 1995;25:240-9.
33. Fanelli MF, Chinen LT, Beqnami MD, Costa WL, Fregnami JH, Soares FA, et al. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61:153-61.
34. Giricz O, Calvo V, Peterson EA, Abouzeid CM, Kenny PA. TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion. Int J Cancer. 2013;133:2587-95.